Recently released data from Eisai’s Phase 3 clinical trial of lecanemab shows that the drug slowed the rate of cognitive decline by 27% as compared to the placebo group in an 18-month study of participants experiencing the early stage of [View More]
Watch Alzheimer's New Jersey CEO Ken Zaentz discuss the impact of Alzheimer's on the New Jersey Morning Show
This weekend as we celebrate Father’s Day, I want to share a message with men who find themselves in the role of caregiver – particularly those in The Silent Generation (1925-1945) and The Baby Boomer Generation (1946-1964) but, this message [View More]
Mother’s Day is celebrated in over 46 countries across the globe. It’s a day to honor the unique and important contributions of the person called Mom. Motherhood is not necessarily about biology. It’s about unconditional love, strength, absolute commitment and [View More]
Actually, it’s both. While the terms "Alzheimer's disease" and "dementia" are often used interchangeably, it's important to know the difference between the two terms, especially when seeking a diagnosis for memory issues. Dementia is not one specific disease. It [View More]
These lyrics from Dan Fogelberg’s 1974 hit Part of the Plan may seem a little unusual as part of a message for the New Year but, as I was listening to the song during the holiday week on my commute [View More]
Updated: November 24, 2021 - Thank you to everyone who contacted the New Jersey Department of Health and the Commissioner to request that New Jersey’s long-term care visitation guidelines be updated to follow the November 12 recommendations issued by the [View More]
In her book, Dementia Reimagined, Tia Powell, MD, director of the Montefiore Albert Einstein Center for Bioethics and professor of psychiatry and bioethics at Albert Einstein College of Medicine, urges us to look at dementia in a different way. [View More]
“We Take Care of Our Own” the Alzheimer’s New Jersey televised benefit that aired in June 2020 on News 12 + has been nominated for a New York Market Emmy Award in the “Community Service” category! This televised [View More]
In a long-awaited decision, the Food and Drug Administration on Monday, June 7, approved Aducanumab as the first new medication for Alzheimer’s disease in nearly two decades and the first to treat the underlying pathology of the disease – not [View More]
